



## Product improvement on TIES Solution from OstomyCure AS.

OstomyCure is proud to announce the further enhancement of its TIES System, a continent ileostomy aimed to alleviate the permanent use of stoma bags attached to the skin.

The TIES Solution comprises a lid with a hatch and a bag holder that clips onto the lid. The bag/pouch is attached to the bag holder, avoiding any contact with the skin.



The TIES Solution has now been further developed to provide an optimal usability and comfort for the patients. OstomyCure believes that these new developments specifically address the issues with current ileostomy bags that cause substantial skin problems and leakage – which are the two most common problems with the existing stoma bag solutions.

“With the new product developments to the lid and the bag-holder we provide the ileostomy patient community with an intuitive and user-friendly

solution that brings their quality of life to the next level.” says Dr. Ben Broennimann, MD & CEO OstomyCure AS and continues: “We now offer a complete solution that not only benefits patients and improve their quality of life, but that also addresses the health economic burden of a large patient group who suffer from this medical condition.”

OstomyCure AS has engaged in a multi-center study (TIES-03) in major clinical centers in the UK & Sweden and recruitment for this study has already started.

OstomyCure AS is a privately-owned Norwegian medical technology company developing a revolutionary technology called the Transcutaneous Implant Evacuation System (TIES®), addressing a market estimated to be worth \$2bn annually.

This solution is intended for ileostomy patients looking for a better solution and improved quality of life.



The stoma market today is dominated by Coloplast, Convatec & Dansac/Hollister but other players such as B. Braun, Medtronic, Johnson & Johnson/Ethicon, Baxter, Salts Healthcare, Welland and Fresenius Kabi also participate.

For more information, please visit [www.ostomycure.com](http://www.ostomycure.com).

Investors Relations :

Dr Ben Broennimann, CEO

[info@ostomycure.com](mailto:info@ostomycure.com)